Spruce Biosciences, Inc. (SPRB) — Analyst outlook / Analyst consensus target is. Based on 11 analyst ratings, the consensus is bullish — 6 Buy, 5 Hold.
The consensus price target is $234.00 (low: $160.00, high: $283.00), representing an upside of 232.4% from the current price $70.39.
Analysts estimate Earnings Per Share (EPS) of $-70.05 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.29 vs est $-70.05 (beat +98.2%). 2025: actual $-50.83 vs est $-21.24 (missed -139.3%). Analyst accuracy: 0%.
SPRB Stock — 12-Month Price Forecast
$234.00
▲ +232.43% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Spruce Biosciences, Inc., the average price target is $234.00, with a high forecast of $283.00, and a low forecast of $160.00.
The average price target represents a +232.43% change from the last price of $70.39.
Highest Price Target
$283.00
Average Price Target
$234.00
Lowest Price Target
$160.00
SPRB Analyst Ratings
Buy
Based on 11 analysts giving stock ratings to Spruce Biosciences, Inc. in the past 3 months
EPS Estimates — SPRB
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.29
vs Est –$70.05
▲ 5,330.1% off
2025
Actual –$50.83
vs Est –$21.24
▼ 58.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — SPRB
96%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024
Actual $0.005B
vs Est $0.005B
▼ 3.7% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
